The US health authorities approved Sitagliptin for marketing, which was recommended to treat diabetes, on Monday, Drug company Zydus Cadila said. The business said its affiliate obtained preliminary clearance for its new Sitagliptin Base 25, 50 and 100 mg tablets from the US Food and Drug Administration (FDA).
In an application for authorisation to commercialise Sitagliptin bases 25, 50 and 100mg tablets, Zydus submitted their new medication application to the USFDA on 31 October 2020. Once the first review cycle was completed on 2 September 2021, Zydus Cadila indicated that the NDA got preliminary clearance.
Zydus Cadila discovers, develops, manufactures, and markets a broad range of healthcare therapies including small molecule drugs, biologic therapeutics, and vaccines.
The group employs around 23,000 people worldwide. The group employs around 23,000 people worldwide.
Antibiotic use has surged globally, leading to a rise in antibiotic resistance, especially concerning in…
Choking is a leading cause of injury and death in young children, particularly those under…
Hard Water (Khara Pani) Leading To Hair Fall Hard water is rich in minerals and…
Discover how the rise in high blood pressure during pregnancy is impacting maternal and fetal…
"Discover the transformative power of six delicious homemade drinks that can help you naturally melt…
"Transform your weight loss routine with these eight delicious fat-flushing drinks that not only hydrate…